Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating ...

US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage ...

Richard Heinberg, a senior fellow with the Post Carbon Institute in Santa Rosa, will be the featured speaker at a weekend ...

Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal. Shares of the ...

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Praxis Precision (PRAX) to $105 from $120 and keeps a Buy rating on the ...

TD Cowen lowered the firm’s price target on Praxis Precision (PRAX) to $61 from $114 and keeps a Buy rating on the shares.Discover the Best ...

FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $132.2, a high estimate of ...